Novartis Ag Adr Stock Price To Earning

NVS Stock

USD 104.75 1.82 1.77%

Novartis AG ADR fundamentals help investors to digest information that contributes to Novartis' financial success or failures. It also enables traders to predict the movement of Novartis Stock. The fundamental analysis module provides a way to measure Novartis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novartis stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Novartis AG ADR Company Price To Earning Analysis

Novartis' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Current Novartis Price To Earning

9.22 X

Most of Novartis' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Novartis Price To Earning Driver Correlations

Understanding the fundamental principles of building solid financial models for Novartis is extremely important. It helps to project a fair market value of Novartis Stock properly, considering its historical fundamentals such as Price To Earning. Since Novartis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novartis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novartis' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Capital Stock	Short Term Debt	Common Stock	Intangible Assets	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Net Tangible Assets	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.91	0.52	0.71	0.92	0.91	0.76	0.0	0.87	0.39	-0.04	0.54	-0.04	0.93	0.74	0.98	-0.06	0.84	0.11	0.38	0.26	-0.35	0.22	0.31	0.23	0.04
Total Stockholder Equity	0.91		0.65	0.43	0.99	0.78	0.75	-0.05	0.59	0.22	0.19	0.25	0.19	0.75	0.43	0.91	-0.31	0.9	0.44	0.26	0.41	-0.24	-0.13	0.21	0.46	0.18
Current Deferred Revenue	0.52	0.65		0.12	0.7	0.33	0.22	-0.24	0.24	0.02	0.14	-0.08	0.14	0.32	0.26	0.47	-0.29	0.46	0.47	0.22	0.5	-0.69	-0.16	0.05	0.32	0.1
Net Debt	0.71	0.43	0.12		0.47	0.6	0.55	0.14	0.87	0.22	-0.2	0.61	-0.2	0.85	0.89	0.68	0.15	0.37	-0.41	0.36	0.15	-0.29	0.6	0.25	-0.02	-0.18
Retained Earnings	0.92	0.99	0.7	0.47		0.78	0.73	-0.03	0.62	0.25	0.14	0.25	0.14	0.77	0.49	0.91	-0.26	0.87	0.41	0.3	0.39	-0.33	-0.08	0.23	0.41	0.2
Accounts Payable	0.91	0.78	0.33	0.6	0.78		0.68	-0.03	0.84	0.44	-0.18	0.5	-0.18	0.87	0.66	0.93	0.01	0.84	-0.05	0.19	0.03	-0.29	0.18	0.14	-0.02	0.02
Net Receivables	0.76	0.75	0.22	0.55	0.73	0.68		-0.16	0.6	0.11	-0.01	0.35	-0.01	0.75	0.5	0.82	-0.23	0.79	0.19	0.28	0.21	0.06	0.09	0.16	0.2	0.01
Short Term Investments	0.0	-0.05	-0.24	0.14	-0.03	-0.03	-0.16		0.06	0.62	-0.01	-0.07	-0.01	0.07	0.14	-0.03	0.14	-0.31	-0.11	0.05	-0.43	0.01	0.18	0.26	0.1	0.75
Total Liab	0.87	0.59	0.24	0.87	0.62	0.84	0.6	0.06		0.5	-0.29	0.75	-0.29	0.92	0.93	0.84	0.25	0.58	-0.31	0.43	0.03	-0.4	0.57	0.35	-0.09	-0.12
Total Current Assets	0.39	0.22	0.02	0.22	0.25	0.44	0.11	0.62	0.5		-0.41	0.38	-0.41	0.37	0.49	0.35	0.41	0.1	-0.2	0.35	-0.59	-0.36	0.47	0.47	-0.2	0.56
Capital Stock	-0.04	0.19	0.14	-0.2	0.14	-0.18	-0.01	-0.01	-0.29	-0.41		-0.27	1.0	-0.19	-0.42	-0.03	-0.78	0.1	0.72	-0.3	0.72	0.48	-0.73	-0.19	0.89	-0.08
Short Term Debt	0.54	0.25	-0.08	0.61	0.25	0.5	0.35	-0.07	0.75	0.38	-0.27		-0.27	0.62	0.63	0.49	0.39	0.29	-0.37	0.6	-0.08	-0.08	0.56	0.48	-0.06	-0.36
Common Stock	-0.04	0.19	0.14	-0.2	0.14	-0.18	-0.01	-0.01	-0.29	-0.41	1.0	-0.27		-0.19	-0.42	-0.03	-0.78	0.1	0.72	-0.3	0.72	0.48	-0.73	-0.19	0.89	-0.08
Intangible Assets	0.93	0.75	0.32	0.85	0.77	0.87	0.75	0.07	0.92	0.37	-0.19	0.62	-0.19		0.83	0.93	0.09	0.69	-0.13	0.43	0.1	-0.31	0.36	0.29	0.05	0.02
Long Term Debt	0.74	0.43	0.26	0.89	0.49	0.66	0.5	0.14	0.93	0.49	-0.42	0.63	-0.42	0.83		0.69	0.36	0.35	-0.39	0.51	-0.02	-0.54	0.73	0.37	-0.2	-0.04
Good Will	0.98	0.91	0.47	0.68	0.91	0.93	0.82	-0.03	0.84	0.35	-0.03	0.49	-0.03	0.93	0.69		-0.13	0.88	0.12	0.31	0.22	-0.28	0.14	0.2	0.21	0.04
Treasury Stock	-0.06	-0.31	-0.29	0.15	-0.26	0.01	-0.23	0.14	0.25	0.41	-0.78	0.39	-0.78	0.09	0.36	-0.13		-0.28	-0.66	0.38	-0.57	-0.3	0.73	0.38	-0.64	0.06
Property Plant Equipment	0.84	0.9	0.46	0.37	0.87	0.84	0.79	-0.31	0.58	0.1	0.1	0.29	0.1	0.69	0.35	0.88	-0.28		0.31	0.07	0.35	-0.09	-0.13	0.04	0.26	-0.08
Net Tangible Assets	0.11	0.44	0.47	-0.41	0.41	-0.05	0.19	-0.11	-0.31	-0.2	0.72	-0.37	0.72	-0.13	-0.39	0.12	-0.66	0.31		0.01	0.57	0.23	-0.73	0.01	0.79	0.27
Deferred Long Term Liab	0.38	0.26	0.22	0.36	0.3	0.19	0.28	0.05	0.43	0.35	-0.3	0.6	-0.3	0.43	0.51	0.31	0.38	0.07	0.01		-0.05	-0.27	0.5	0.79	0.03	0.11
Long Term Investments	0.26	0.41	0.5	0.15	0.39	0.03	0.21	-0.43	0.03	-0.59	0.72	-0.08	0.72	0.1	-0.02	0.22	-0.57	0.35	0.57	-0.05		0.08	-0.39	-0.11	0.71	-0.4
Short Long Term Debt	-0.35	-0.24	-0.69	-0.29	-0.33	-0.29	0.06	0.01	-0.4	-0.36	0.48	-0.08	0.48	-0.31	-0.54	-0.28	-0.3	-0.09	0.23	-0.27	0.08		-0.42	-0.15	0.36	-0.12
Long Term Debt Total	0.22	-0.13	-0.16	0.6	-0.08	0.18	0.09	0.18	0.57	0.47	-0.73	0.56	-0.73	0.36	0.73	0.14	0.73	-0.13	-0.73	0.5	-0.39	-0.42		0.47	-0.55	-0.07
Cash And Equivalents	0.31	0.21	0.05	0.25	0.23	0.14	0.16	0.26	0.35	0.47	-0.19	0.48	-0.19	0.29	0.37	0.2	0.38	0.04	0.01	0.79	-0.11	-0.15	0.47		0.09	0.31
Net Invested Capital	0.23	0.46	0.32	-0.02	0.41	-0.02	0.2	0.1	-0.09	-0.2	0.89	-0.06	0.89	0.05	-0.2	0.21	-0.64	0.26	0.79	0.03	0.71	0.36	-0.55	0.09		0.1
Net Working Capital	0.04	0.18	0.1	-0.18	0.2	0.02	0.01	0.75	-0.12	0.56	-0.08	-0.36	-0.08	0.02	-0.04	0.04	0.06	-0.08	0.27	0.11	-0.4	-0.12	-0.07	0.31	0.1

Click cells to compare fundamentals

Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Competition

Predict Novartis

Novartis Retained Earnings

Retained Earnings

57.98 Billion

At this time, Novartis' Retained Earnings are comparatively stable compared to the past year.

Based on the latest financial disclosure, Novartis AG ADR has a Price To Earning of 9.22 times. This is 64.32% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The price to earning for all United States stocks is 67.9% higher than that of the company.

Novartis Price To Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.

Novartis is currently under evaluation in price to earning category among its peers.

Novartis Fundamentals

	Return On Equity	0.29
	Return On Asset	0.11
	Profit Margin	0.35 %
	Operating Margin	0.33 %
	Current Valuation	225.01 B
	Shares Outstanding	2 B
	Shares Owned By Institutions	6.73 %
	Number Of Shares Shorted	4.42 M
	Price To Earning	9.22 X
	Price To Book	4.83 X
	Price To Sales	4.19 X
	Revenue	46.66 B
	Gross Profit	37.87 B
	EBITDA	18.29 B
	Net Income	8.57 B
	Cash And Equivalents	4.64 B
	Cash Per Share	8.84 X
	Total Debt	26.35 B
	Debt To Equity	0.47 %
	Current Ratio	1.31 X
	Book Value Per Share	21.67 X
	Cash Flow From Operations	14.46 B
	Short Ratio	3.70 X
	Earnings Per Share	5.73 X
	Price To Earnings To Growth	3.14 X
	Target Price	112.67
	Number Of Employees	76.06 K
	Beta	0.51
	Market Capitalization	209.42 B
	Total Asset	99.94 B
	Retained Earnings	49.65 B
	Working Capital	4.09 B
	Current Asset	22.84 B
	Current Liabilities	23.71 B
	Annual Yield	0.04 %
	Five Year Return	3.53 %
	Net Asset	99.94 B
	Last Dividend Paid	3.92

About Novartis Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC